BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 7512706)

  • 1. Triploid partial molar pregnancy detected through maternal serum alpha-fetoprotein and HCG screening.
    Harper MA; Ruiz C; Pettenati MJ; Rao PN
    Obstet Gynecol; 1994 May; 83(5 Pt 2):844-6. PubMed ID: 7512706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Triploid partial molar pregnancy and fetal neural tube defect detected through Down's syndrome screening.
    Quintieri F; Idotta R
    Clin Exp Obstet Gynecol; 1996; 23(3):181-3. PubMed ID: 8894330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A prospective evaluation of a second-trimester screening test for fetal Down syndrome using maternal serum alpha-fetoprotein, hCG, and unconjugated estriol.
    Cheng EY; Luthy DA; Zebelman AM; Williams MA; Lieppman RE; Hickok DE
    Obstet Gynecol; 1993 Jan; 81(1):72-7. PubMed ID: 7677967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Triploidy identified through second-trimester serum screening.
    Huang T; Alberman E; Wald N; Summers AM
    Prenat Diagn; 2005 Mar; 25(3):229-33. PubMed ID: 15791661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prenatal screening using maternal serum alpha-fetoprotein, human chorionic gonadotropin, and unconjugated estriol: two-year experience in a health maintenance organization.
    McDuffie RS; Haverkamp AD; Stark CF; Haverkamp C; Barth CK
    J Matern Fetal Med; 1996; 5(2):70-3. PubMed ID: 8796771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unexplained elevated midtrimester maternal serum levels of alpha fetoprotein, human chorionic gonadotropin, or low unconjugated estriol: recurrence risk and association with adverse perinatal outcome.
    Wax JR; Lopes AM; Benn PA; Lerer T; Steinfeld JD; Ingardia CJ
    J Matern Fetal Med; 2000; 9(3):161-4. PubMed ID: 10914623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 'Dual positivity' for neural tube defects and down syndrome at maternal serum screening: gestational outcome.
    Zanini R; Tarantini M; Cerri V; Jacobello C; Bellotti D; Lancetti S; Scalchi S; Groli C; Bianchi UA
    Fetal Diagn Ther; 1998; 13(2):106-10. PubMed ID: 9650657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First trimester diagnosis of partial mole.
    Phupong V; Triratanachat S; Promchainant C; Ultchaswadi P
    Arch Gynecol Obstet; 2005 Sep; 272(3):235-7. PubMed ID: 15875207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pre-eclampsia and peripartum cardiomyopathy in molar pregnancy: clinical implication for maternally imprinted genes.
    Billieux MH; Petignat P; Fior A; Mhawech P; Blouin JL; Dahoun S; Vassilakos P
    Ultrasound Obstet Gynecol; 2004 Apr; 23(4):398-401. PubMed ID: 15065193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of combining maternal serum alpha-fetoprotein and hCG in a second-trimester screening program for Down syndrome.
    Mooney RA; Peterson CJ; French CA; Saller DN; Arvan DA
    Obstet Gynecol; 1994 Aug; 84(2):298-303. PubMed ID: 7518896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eclampsia complicating hydatidiform molar pregnancy with a coexisting, viable fetus. A case report.
    Ramsey PS; Van Winter JT; Gaffey TA; Ramin KD
    J Reprod Med; 1998 May; 43(5):456-8. PubMed ID: 9610471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maternal serum screening.
    Carroll JC
    Can Fam Physician; 1994 Oct; 40():1756-64. PubMed ID: 7524838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 46,XY,i(21q) identified by maternal serum screening.
    Meyers CM; Ghori S; Roberson AE; Blitzer MG; Cohen MM
    Md Med J; 1997 Feb; 46(2):88-9. PubMed ID: 9029908
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Are Down syndrome fetuses detected through maternal serum screening similar to those remaining undetected?
    Christiaens GC; Hagenaars AM; Akkerman C; De France HF
    Prenat Diagn; 1996 May; 16(5):437-42. PubMed ID: 8844002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prenatal diagnosis of a deletion of 18q in a fetus associated with multiple-marker screen positive results.
    Chen CP; Chern SR; Liu FF; Jan SW; Lee CC; Chang YC; Yue CT
    Prenat Diagn; 1997 Jun; 17(6):571-6. PubMed ID: 9203216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Maternal serum screening for neural tube defects and fetal chromosome abnormalities.
    Rose NC; Mennuti MT
    West J Med; 1993 Sep; 159(3):312-7. PubMed ID: 7694429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current management of complete and partial molar pregnancy.
    Goldstein DP; Berkowitz RS
    J Reprod Med; 1994 Mar; 39(3):139-46. PubMed ID: 8035368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maternal serum testing for alpha-fetoprotein and human chorionic gonadotropin in high-risk pregnancies.
    Jauniaux E; Gulbis B; Tunkel S; Ramsay B; Campbell S; Meuris S
    Prenat Diagn; 1996 Dec; 16(12):1129-35. PubMed ID: 8994249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Second-trimester maternal serum alpha-fetoprotein, human chorionic gonadotropin, and unconjugated oestriol after early transvaginal multifetal pregnancy reduction.
    Groutz A; Amit A; Yaron Y; Yovel I; Wolman I; Legum C; Lessing JB
    Prenat Diagn; 1996 Aug; 16(8):723-7. PubMed ID: 8878282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. hCG and the free beta-subunit as screening tests for Down syndrome.
    Knight GJ; Palomaki GE; Neveux LM; Fodor KK; Haddow JE
    Prenat Diagn; 1998 Mar; 18(3):235-45. PubMed ID: 9556040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.